PLENAXIS
LOE Approachingabarelix
NDAINTRAMUSCULARPOWDERPriority Review
Approved
Nov 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PLENAXIS (abarelix) is a gonadotropin-releasing hormone (GnRH) antagonist administered as an intramuscular injection for the treatment of advanced prostate cancer. It works by rapidly suppressing testosterone production, providing an alternative to GnRH agonists with a faster onset of action and reduced initial testosterone flare risk. The product was approved in 2003 and represents a distinct mechanism within androgen deprivation therapy.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30% intensity); team size and investment likely contracting as generic/biosimilar entry approaches.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PLENAXIS offers limited career momentum given its approaching loss of exclusivity and minimal active headcount (0 linked jobs). Roles on this product are primarily defensive—managing market share decline, handling payer negotiations, and transition planning—rather than building commercial scale. Career development here is constrained; professionals may use it as a stepping stone to larger, growth-stage oncology franchises.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.